SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Champlin, R. E. Articles by Golde, D. W. Search for Related Content PubMed PubMed Citation Articles by Champlin, R. E. Articles by Golde, D. W. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor RE Champlin, SD Nimer, P Ireland, DH Oette and DW Golde UCLA Center for Health Sciences 90024-1678. Fifteen patients with refractory aplastic anemia or agranulocytosis received treatment with recombinant human granulocyte-macrophage-colony- stimulating factor (rhGM-CSF) in doses from 4 to 64 micrograms/kg/d by continuous intravenous (IV) infusion. Ten of 11 evaluable patients with aplastic anemia had substantial increments in granulocytes, monocytes, and eosinophils associated with myeloid and eosinophilic hyperplasia in the bone marrow. Patients with pretreatment granulocytes greater than 0.3 x 10(9)/L had greater increments in circulating myeloid cells than patients with more severe granulocytopenia. Only one patient had improvement in erythrocytes and platelets. Blood counts fell to baseline after rhGM-CSF treatment was discontinued. Doses up to 16 micrograms/kg/d were relatively well tolerated in the absence of extreme leukocytosis. Fatigue and myalgia were common. Three patients developed pulmonary infiltrates that resolved with discontinuation of treatment. Patients tended to have recurrent inflammation in previously diseased tissues. These data indicate that rhGM-CSF will increase circulating granulocytes, monocytes, and eosinophils in patients with refractory aplastic anemia. Further studies are necessary to determine if rhGM-CSF treatment will reduce morbidity or improve survival. Volume 73, Issue 3, pp. 694-699, 02/15/1989 Copyright © 1989 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. M. Lindley and T. R. Gordon Application of Biotechnology Products in Oncology Journal of Pharmacy Practice, January 1, 1991; 4(2): 117 - 130. [PDF]

	Copyright © 1989 by American Society of Hematology         Online ISSN: 1528-0020